Although prevalence estimates for several significant proteins in this study were lower than other T1DM autoantibodies, such as GAD2 with a prevalence of about 80% in new-onset T1DM [2, 48], clinically important indicators of disease progression need not have high prevalence. The gene discussed is GAD2; the disease is type 1 diabetes mellitus.